Brain metabolism in Alzheimer disease and vascular dementia assessed by in vivo proton magnetic resonance spectroscopy

Psychiatry Research - Neuroimaging

Volumn 123, Issue 3, 2003, Pages 183-190

  Herminghaus, Sebastian ^a   Frölich, Lutz ^a   Gorriz, Corrina ^a   Pilatus, Ullrich ^a   Dierks, Thomas ^b   Wittsack, Hans Jörg ^a   Lanfermann, Heinrich ^a   Maurer, Konrad ^a   Zanella, Friedhelm E ^a  

^a GOETHE UNIVERSITY   (Germany)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

Brain; Metabolism; NMR spectroscopy

Indexed keywords

INOSITOL; MYELIN;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN ATROPHY; BRAIN CORTEX; BRAIN METABOLISM; BRAIN REGION; CELL LOSS; CONTROLLED STUDY; GLIOSIS; HUMAN; IN VIVO STUDY; MAJOR CLINICAL STUDY; MEMORY; METABOLITE; MULTIINFARCT DEMENTIA; NEUROCHEMISTRY; PARIETAL LOBE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTON NUCLEAR MAGNETIC RESONANCE; TEMPORAL LOBE; TOPOGRAPHY;

EID: 0043092247     PISSN: 09254927     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0925-4927(03)00071-4     Document Type: Article

References (51)

1. Antuono P.G., Jones J.L., Wang Y., Li S.J. Decreased glutamate+glutamine in Alzheimer's disease detected in vivo with (1)H-MRS at 0.5 T. Neurology. 27:2001;737-742.
2. Berridge M.J. Inositol trisphosphate and calcium signalling. Nature. 361:1984;487-489.
3. Braak H., Braak E., Bohl J. Staging of Alzheimer-related cortical destruction. European Neurology. 33:1993;403-408.
4. Brand A., Richter-Landsberg C., Leibfritz D. Multinuclear NMR studies on the energy metabolism of glial and neuronal cells. Development in Neurosciences. 15:1993;289-298.
5. 1H MR spectroscopy. AJNR American Journal of Neuroradiology. 21:2000;621-630.
6. 1H-MR spectroscopy differentiates mild cognitive impairment from normal brain aging. Neuroreport. 8:2001;2315-2317.
7. Constans J.M., Meyerhoff D.J., Gerson J., McKay S., Norman D., Fein G., Weiner M.W. H-1 MR spectroscopic Imaging of white matter signal hyperintensities: Alzheimer disease and ischemic vascular dementia. Radiology. 197:1995;517-523.
8. Dilling H., Freyberger H.J., Malchow C.P. Design of the ICD-10 field trial in German-speaking countries. Pharmacopsychiatry. 23:(Suppl. 4):1990;142-145.
9. Ernst T., Chang L., Melchor R., Mehringer R. Frontotemporal dementia and early Alzheimer disease: differentiation with frontal lobe H-1 MR spectroscopy. Radiology. 203:1997;829-838.
10. Ernst T., Kreis R., Ross B.D. Absolute quantification of water and metabolites in the human brain. I. Compartments and water. Journal of Magnetic Resonance. Series B. 102:1993;1-8.
11. Erzigkeit H. Manual zum SKT, Formen A-E. 4th ed:1989;Beltz, Weinheim, Germany.
12. Folstein M., Folstein S.E., McHugh P.R. 'Mini Mental State', a practical method of grading the cognitive decline of patients for the clinician. Journal of Psychiatric Research. 12:1975;189-198.
13. Frahm J., Bruhn H., Gyngell M.L., Merboldt K.D., Hanicke W., Sauter R. Localized high-resolution proton NMR spectroscopy using stimulated echoes: initial applications to human brain in vivo. Magnetic Resonance in Medicine. 9:1989;79-93.
14. Friedmann P., Wallin A., Blennow K., Davidsson P., Gottfries C.G., Svennerholm L. Sulfatide as a biochemical marker in cerebrospinal fluid of patients with vascular dementia. Acta Neurologica Scandinavica. 85:1992;103-106.
15. Gottfries C.G., Blennow K., Karlsson I., Wallin A. The neurochemistry of vascular dementia. Dementia. 5:1994;163-167.
16. 1HMR chemical shift selective (CHESS) imaging. Physics in Medicine and Biology. 30:1985;341-344.
17. Hachinsky V.C., Liff L.D., Zilkha E., Duboulay G.H., McAllister V.L., Marshall J., Ross-Russell R.W., Symon L. Cerebral blood flow in dementia. Archives of Neurology. 32:1975;632-637.
18. Hattori N., Abe K., Sakoda S., Sawada T. Proton MR spectroscopic study at 3 Tesla on glutamate/glutamine in Alzheimer's disease. Neuroreport. 13:2002;183-186.
19. 1H-magnetic resonance spectroscopy of human brain: influence of composition and parameterization of the basis set in linear combination model-fitting. Magnetic Resonance in Medicine. 48:2002;440-453.
20. Hsu Y.Y., Du A.T., Schuff N., Weiner M.W. Magnetic resonance imaging and magnetic resonance spectroscopy in dementias. Journal of Geriatric, Psychiatry and Neurology. 14:2001;145166.
21. Huang, W., Alexander, G.E., Chang, L., Krasuski, J.S., Rapoport, S.I., Schapiro, M.B., 1997. Correlation of brain metabolite concentration with dementia severity in Alzheimers disease. 5th proceedings and exhibition of International Society of Magnetic Resonance in Medicine, p. 137.
22. Hubbard B.M., Anderson J.M. Age related neuron content of the cerebral cortex in senile dementia of Alzheimer-type. Neuropathology and Applied Neurobiology. 11:1981;369-382.
23. Jessen F., Block W., Traber F., Keller E., Flacke S., Papassotiropoulos A., Lamerichs R., Heun R., Schild H.H. Proton MR spectroscopy detects a relative decrease of N-acetylaspartate in the medial temporal lobe of patients with AD. Neurology. 55:2000;684-688.
24. Jolles J., Bothmer J., Markerink M., Ravid R. Phosphatidylinositol kinase is reduced in Alzheimer's disease. Journal of Neurochemistry. 58:1992;2326-2338.
25. Klunk W.E., Panchalingam K., Moossy J., McClure R.J., Pettegrew J.W. N-Acetyl-L-aspartate and other amino acid metabolites in Alzheimer's diseased brain. Neurology. 42:1992;1578-1585.
26. Klunk W.E., Xu K., Panchalingam R.J., McClure, Pettegrew J.W. Quantitative 1H and 31P MRS of PCA extracts of postmortem Alzheimer's diesease brain. Neurobiology of Aging. 17:1996;349-357.
27. Loeb C., Meyer J.S. Vascular dementia: still a debatable entity. Journal of Neurological Sciences. 143:1996;31-40.
28. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E.M. Clinical diagnosis of Alzheimer's disease. Report of the NINCDS-ADRDA group. Neurology. 34:1984;939-944.
29. 1H NMR spectroscopy: N-acetyl-L-aspartate, creatine and choline. NMR in Biomedicine. 4:1991;47-52.
30. Miller B.L., Moats R.A., Shonk T., Ernst T., Woolley S., Ross B.D. Alzheimer disease: depiction of cerebral myo-inositol with proton MR spectroscopy. Radiology. 187:1993;433-437.
31. Moats R.A., Ernst T., Shonk T.K., Ross B.D. Abnormal cerebral metabolite concentrations in patients with probable Alzheimer disease. Magnetic Resonance in Medicine. 32:1994;110-115.
32. Nadler J.V., Cooper J.R. N-Acetyl-aspartic acid content of human neural tumors and bovine peripheral nervous tissue. Journal of Neurochemistry. 19:1971;313-319.
33. Oldfield R.C. The assessment and analysis of handedness: the Edinburgh Inventory. Neuropsychologia. 9:1971;97-113.
34. Provencher S.W. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magnetic Resonance in Medicine. 30:1993;672-679.
35. Provencher S.W. Automatic quantification of localized in vivo 1H spectra with LC Model. NMR in Biomedicine. 14:2001a;260-264.
36. Provencher, S.W., 2001b homepage: sp@s-provencher.com.
37. Reisberg B., Ferris S.H., de Leon M.J., Crook T. The Global Deterioration Scale (GDS) for assessment of primary degenerative dementia. American Journal of Psychiatry. 139:1982;1136-1139.
38. Roman G.C., Tatemichi T.K., Erkinjuntti T., Cummings J.L., Masdeu J.C., Garcia J.H., Amaducci L., Orgogozo J.M., Brun A., Hofman A. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology. 43:1993;250-260.
39. Ross B.D. Biochemical considerations on 1H spectroscopy. Glutamate and glutamine; myo-inositol and related metabolites. NMR in Biomedicine. 4:1990;59-63.
40. Ross B., Michaelis T. Clinical applications of magnetic resonance spectroscopy. Magnetic Resonance Quarterly. 10:1994;191-247.
41. Ross B.D., Blüml S., Cowan R., Danielsen E., Farrow N., Gruetter R. In vivo magnetic resonance spectroscopy of the human brain: the biophysical basis of dementia. Biophysical Chemistry. 68:1997;161-172.
42. Schoene W.C. Degenerative diseases of the central nervous system. Davis R.L., Robertson D.M. Textbook of Neuropathology. 1985;788-823 Williams and Wilkins, Baltimore.
43. Schirmer T., Auer D.P. On the reliability of quantitative clinical magnetic resonance spectroscopy of the human brain. NMR in Biomedicine. 13:2000;28-36.
44. Scott S.A. Dendritic atrophy and remodeling of amygdaloid neurons in Alzheimer's disease. Dementia. 4:1993;264-272.
45. Shonk T., Moats R.A., Gifford P., Michaelis T., Mandigo J., Izumi J., Ross B.D. Probable Alzheimer disease: diagnosis with proton MR spectroscopy. Radiology. 195:1995;65-72.
46. Stokes C.E., Hawthorne J.N. Reduced phosphoinositide concentration in anterior temporal cortex of Alzheimer-diseased brains. Journal of Neurochemistry. 48:1987;1018-1021.
47. Stoppe G., Bruhn H., Pouwels P.J., Hanicke W., Frahm J. Alzheimer disease: absolute quantification of cerebral metabolites in vivo using localized proton magnetic resonance spectroscopy. Alzheimer Disease and Associated Disorders. 14:2000;112-119.
48. Swaab D.F., Hofman M.A., Lucassen P.J., Salehi A., Uylings H.B.M. Neuronal atrophy, not cell death, is the main hallmark of Alzheimer's disease. Neurobiology of Aging. 15:1994;369-371.
49. Terry R.D., Masliah E., Salmon D.P., Butters N., DeTeresa R., Hill R., Hansen L.A., Katzmann R. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Annals of Neurology. 30:1991;572-580.
50. Valenzuela M.J., Sachdev P. Magnetic resonance spectroscopy in AD. Neurology. 56:2001;592-598.
51. Wallin A., Gottfries C.G., Karlsson I. Decreased myelin lipids in Alzheimer's disease and vascular dementia. Acta Neurologica Scandinavica. 80:1989;319-323.